anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a novel purified isozyme of an autoclavable superoxide dismutase extracted from the plant  Potentilla astrisanguinea  Lodd. Var.  orgyrophylla,  said isozyme having the following characteristics, O 2   −.  scavenging activity remains same before and after autoclaving; scavenges O 2   −.  from sub-zero temperature of −20° C. to high temperature of +80° C.; O 2   −.  scavenging activity at 25° C. for 30 days without adding any stabilizing agent such as polyols or sugars; O 2   −.  scavenging activity in the presence of saline (0.9% sodium chloride) to 61.8% of the control (without 0.9% sodium chloride), stable at 4° C. for at least 8 months; contamination free and infection free from any living micro- and/ or macro-organism after autoclaving; possesses temperature optima at 0° C.; possesses a molecular weight of 33 kD under non-denaturating conditions; possesses a molecular weight of 36 kD under denaturating conditions; has clear peaks in UV range at 268 and 275 nm; has an enzyme turnover number of 19.53×10 4 % per nmol per min at 0° C.; and requires Cu/Zn as a co-factor, method for the preparation of the purified isozyme of autoclavable superoxide dismutase and formulations containing the said autoclavable superoxide dismutase.
FIELD: medical engineering. SUBSTANCE: composition has salcatonin - 100-5000 MU, NaCl - 9 mg, HCl - up to pH 3.5-4.5, purified water - up to 1 ml. The first version of the composition is: salcatonin - 500 MU, NaCl - 9 mg, HCl - up to pH 4, purified water - up to 1 ml. The second version of the composition is: salcatonin - 1000 MU, NaCl - 9 mg, HCl - up to pH 4, purified water - up to 1 ml. The device has reservoir 1 to be filled with the composition, and dosing unit 5 having spring-loaded valve engageable with push rod 12. The dosing unit 5 has casing 6 having several communicating chambers and piston 13 in its cavity. The piston is engageable with valve spring 14, valve head 17 is made in the upper part of piston 13. Saddle surface 18 of the valve is formed in the body of rod 12 having passing duct 22 and protruding above reservoir neck. Upper chamber 10 is formed between piston 13 and internal wall of casing 6. It has toroidal shape and enables pressure to be created due to rod 12 traveling to cause valve head 17 to be brought aside from saddle surface 18. The reservoir has its upper space portion to be filled with nitrogen under excessive pressure of 0.2-0.3 bar. Sealing ring is settleable between casing 6 of dosing unit 5 and reservoir neck. Advantageous variant of volume of reservoir 1 is 7 ml. Dosing unit 5 is to produce output of about 100 mcl per each operation that approximately corresponds to volume of toroidal chamber 10. The pharmaceutical package has spraying device with reservoir containing pharmaceutical composition. EFFECT: enhanced effectiveness in treating osteoporosis, Paget disease, hypercalcemia and the like diseases. 12 cl, 2 dwg
<P>PROBLEM TO BE SOLVED: To provide a percutaneous patch that is excellent in immediate effectiveness of a medicine and excellent also in retention of the effects of the medicine.  <P>SOLUTION: The percutaneous patch 1a includes a supporting substrate 10a, and a first medicine-containing part 11a and a second medicine-containing part 12a which are formed on the supporting substrate 10a and contain a medicine. The first medicine-containing part 11a releases the medicine to the skin faster than the second medicine-containing part 12a. The second medicine-containing part 12a is installed so that it surrounds the first medicine-containing part 11a. A percutaneous absorption-accelerating agent for accelerating absorption of the medicine into the skin is contained in the first medicine-containing part 11a. A gap 13a as an inhibiting means for inhibiting migration of the medicine is formed between the first medicine-containing part 11a and the second medicine-containing part 12a.  <P>COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To obtain a drug preparation having improve immediate action, slowly releasing property and bioavailability of the drug components, suppressing side effects and effective in absorbing vaporized drug components through the nose or mouth into the body, by including a drug component into a fibrous substance consisting of micro-porous hollow fibers. CONSTITUTION:A vaporizable drug is included in a fibrous substance (e.g. woolly material, a flat material such as nonwoven cloth, etc.) composed of hollow fibers having a number of fine pores through out the whole surface of the fiber, wherein at least a part of the pores are extended from the surface to the hollow part. Preferably the hollow ratio is >=5% and the ratio of the pores extending from the surface to the hollow part of the the fiber to the cross-sectional area of the fiber is 0.001-70wt% especially 1-50% based on the cross-sectional area excluding the hollow part. The drug applicable in the above preparation is an antipyretic analgesic anti-inflammatory agent such as camphor, methyl salicylate, etc., coronary vasodilator such as nitroglycerin, anti-histaminic agent such as diphenhydramine and beta-blocker such as propranolol.
This group will undergo appropriate cancer surgery for each patient with pelvic lymph node dissection +/- para-aortic lymph node dissection. At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
BACKGROUND: Haematological malignancies (blood cancers) often follow chronic trajectories that can span many months or years. Management of these diseases typically involves periods of 'Watch & Wait', whereby patients are monitored by the hospital and only treated at progression, if or when this occurs, which might be never or on multiple occasions. Such remitting-relapsing pathways are unpredictable and can cause anxiety and distress. This study aimed to generate evidence about information preferences, with a view to underpinning future patient-facing resources; potentially mitigating psycho-social difficulties and promoting effective shared decision-making.
METHODS: A qualitative study was conducted, set within a UK population-based cohort of patients with haematological malignancies. Sampling was purposive, based on age (initially around the median age of diagnosis) and disease subtype (chronic lymphocytic leukaemia, follicular lymphoma, marginal zone lymphoma and myeloma); and in-depth interviews took place with 35 patients (10 with relatives). Analysis drew on qualitative description and thematic content analysis and included critical reading and annotation of transcripts, identification of common and rare phenomena, generation of codes and coding of material, and theme development.
RESULTS: Patients discussed their preferences and experiences at length and rich data were generated from diagnosis onwards, across diagnostic subtypes. The overarching theme identified was 'Variations in preferences' with needs seen to differ from person to person; as well as changing over time for individuals. Five sub-themes were identified: 1) To know or not to know? 2) Needs are dynamic; 3) The polarising issue of prognosis; 4) Preferred sources; and 5) Differences in content, depth and presentation.
CONCLUSIONS: Varied, dynamic information preferences indicate that resources should be developed in a way that provides maximum choice, enabling patients to select relevant material at different time-points on their trajectory. The development of blood cancer subtype-specific "real-world clinical scenarios" could improve patient experiences and inform shared decision-making.
Sumatriptan injection, USP contains sumatriptan succinate, a selective 5-HT1B/1D receptor agonist. Sumatriptan succinate is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide succinate (1:1), and it has the following structure:

The empirical formula is C14H21N3O2S∙C4H6O4, representing a molecular weight of 413.5. Sumatriptan succinate is a white to off-white powder that is readily soluble in water and in saline. Sumatriptan injection, USP is a clear, colorless to pale yellow, sterile, nonpyrogenic solution for subcutaneous injection. Each 0.5 mL of Sumatriptan injection USP, 12 mg/mL solution contains 8.4 mg of sumatriptan succinate equivalent to 6 mg of sumatriptan and 3.5 mg of sodium chloride, USP in water for injection, USP. The pH range of the solution is approximately 4.2 to 5.3. The osmolality of the injection is 291 mOsmol.
Patients receive general education exercise packet with instruction to exercise regularly for up to 150 minutes weekly. Patients also wear a FitBit daily over 16 weeks.
Pulmonary hypertension (PH) can affect both pulmonary arterial tree and cardiac function, often leading to right heart failure and death. Despite the urgency, the lack of understanding has limited the development of effective cardiac therapeutic strategies. Our research reveals that MCJ modulates mitochondrial response to chronic hypoxia. MCJ levels elevate under hypoxic conditions, as in lungs of patients affected by COPD, mice exposed to hypoxia, and myocardium from pigs subjected to right ventricular (RV) overload. The absence of MCJ preserves RV function, safeguarding against both cardiac and lung remodeling induced by chronic hypoxia. Cardiac-specific silencing is enough to protect against cardiac dysfunction despite the adverse pulmonary remodeling. Mechanistically, the absence of MCJ triggers a protective preconditioning state mediated by the ROS/mTOR/HIF-1α axis. As a result, it preserves RV systolic function following hypoxia exposure. These discoveries provide a potential avenue to alleviate chronic hypoxia-induced PH, highlighting MCJ as a promising target against this condition.
Prospective phase II non controlled study. Staging: All patients will be submitted to a local Magnetic Resonance (MR), Chest Tomography (CT) and Positron emission tomography-computed tomography (PET CT) previous to treatment. After the first cT cycle a new PET CT will be provided and one more at the end of the neoadjuvant treatment. Chemotherapy: cT neoadjuvant: Doxorubicin 75mg/m2 (cycles 1,2 and 3), and ifosfamide 9 g/m2 (cycles 1 and 3). Radiotherapy: RT 25 Gy / 5 x 500 cGy/day, beginning at Cycle 2/Day1. The surgery will be performed after 4-6 weeks from cycle 3. The remain of viable cells in surgical specimen will be analyzed and whether the the percentage value is less than 30% the patient will receive more 3 cycles of cT. A boost of RT is indicated if margins are considered R1 (microscopic positive margin).
Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions. Sixty seconds of rest will be given between sets.
After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training. The internal mental visualization format (as if the students were doing the events themselves) was preferred for the imagery technique. The content of the scenarios was examined by three academic nurses who completed their doctoral education in addition to the authors, and expert opinions were taken. The flow of the scenarios was discussed with the experts until a consensus was reached and the final scenario was created. This technique lasted approximately 30-35 minutes.
Means for the surface treatment of dental pieces, in particular polishes, abrasives and blast compounds, contain quartz from crystallised silicon dioxide. This has proved to be unhealthy. The object of the invention is therefore to provide a means which does not pose the risk of health damage. In the means according to the invention, quartz has been replaced by a quartz-free igneous rock, in particular nepheline-syenite. It was found, surprisingly, that igneous rock in powdered form gives treatment results which are almost identical to those of conventional means containing quartz. The means according to the invention is particularly suitable for polishing and blasting dental pieces, especially those made of plastics.
HAT1 topical solution will come in a labeled spray bottle. This topical medicated solution will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
The invention relates to a plaster carrier absorbing medicine for external application and a preparation method of the plaster. Active absorbing materials 2 are filled between covering face 1 and applied part binding face 3 made of air-permeable shell fabrics on the plaster carrier. The active absorbing materials are activated carbon granules, or zeolite granules, or molecular sieve granules. An instant adhesive tape 4 is arranged around the applied part binding face. The preparation method of the plaster absorbing medicine for external application is as follows: extracting medicine raw materials with solvent, heating under reflux, obtaining liquid medicine infusion after concentrating, using the plaster carrier to absorb the liquid medicine infusion, packing under vacuum, instantly sterilizing and casing. The invention not only effectively improves air permeability, but also is helpful for effective components of medicine to smoothly pass through and completely take effect, overcomes phenomena of itch, blisters, cankers and hypersusceptibility cause by airtightness. Because no substrate is in existence, stimulus of a substrate to skin is avoided, and effect of effective components of the medicine is obviously improved.
With advancing age, the incidence of sarcopenia increases, eventually leading to a cascade of adverse events. However, there is currently a lack of effective pharmacological treatment for sarcopenia. Sodium-glucose co-transporter 2 inhibitor (SGLT2i) empagliflozin demonstrates anti-fibrotic capabilities in various organs. This study aims to determine whether empagliflozin can improve skeletal muscle fibrosis induced by sarcopenia in naturally aging mice. A natural aging model was established by feeding male mice from 13 months of age to 19 months of age. A fibrosis model was created by stimulating skeletal muscle fibroblasts with TGF-β1. The Forelimb grip strength test assessed skeletal muscle function, and expression levels of COL1A1, COL3A1, and α-SMA were analyzed by western blot, qPCR, and immunohistochemistry. Additionally, levels of AMPKα/MMP9/TGFβ1/Smad signaling pathways were examined. In naturally aging mice, skeletal muscle function declines, expression of muscle fibrosis markers increases, AMPKα expression is downregulated, and MMP9/TGFβ1/Smad signaling pathways are upregulated. However, treatment with empagliflozin reverses this phenomenon. At the cellular level, empagliflozin exhibits similar anti-fibrotic effects, and these effects are attenuated by Compound C and siAMPKα. Empagliflozin exhibits anti-fibrotic effects, possibly associated with the AMPK/MMP9/TGFβ1/Smad signaling pathways.
Virtual Reality (VR) is a powerful and inexpensive technology that has been effectively used in healthcare settings to treat anxiety and pain, with minimal side effects. In the last two decades, opioid abuse and deaths related to opioids have increased, and opioid naive patients are at increased risk of opioid abuse when opioids are used during their surgical procedures. In addition, anesthetics, anxiolytics and analgesics, namely opioids, have a myriad of side effects that worsen patient experience, and lead to complications and increased costs. There are limited studies on the use of VR in the perioperative setting. Our study is a randomized controlled trial to investigate the use of VR to treat anxiety and pain in perioperative settings. We will recruit 56 patients, 28 in the control group and 28 in the VR group, undergoing short (\<2 hrs) hand or upper extremity surgeries under local anesthesia and monitored anesthesia care (MAC). The control group will receive standard anesthetic management and the VR group will be exposed to VR in the preoperative setting and during the surgical procedure, using the clinically validated AppliedVR software. The data collected will included satisfaction questionnaires and pain scores for anxiety/pain pre- and post- procedure, vital signs trends to assess sympathetic response during surgery, and amount of anesthetics used. We hypothesize that the VR group will show decreased anxiety and pain, increased satisfaction, and decreased use of anesthetics during the procedure.
The first group will be monitored by Inbody S20 analysis to measure fluid status. The Bioimpedance will be measured each time prior to hemodialysis session . The value of BIA measurement of more than 0.4 will be considered as edema.
Subjects assigned to the control arm will complete the prescribed 2-month treatment. The OT will follow the "Control Arm Intervention Protocol" to design and prescribe the home exercise program. The OT will complete weekly phone calls with the participant to check on progress, adherence, and update the exercises as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the control intervention will be 7 hours/week. The minimum amount of time spent on the control intervention will be 3.5 hours/week.
Only two hospitals in France can take care patients with TIA or MS in an outpatient setting :Bichat hospital in Paris and Toulouse University Hospital. The effectiveness of this management has been demonstrated since recurrence stroke risk is reduced by 80% at one year. An English study (EXPRESS study) \[2\] showed a gain of 624 pounds with an ambulatory management compared to a conventional one. No studies are available in France on this subject.

The aim of this study is to test the feasibility of a collection of medical and economic data on a prospective way. The investigators collect medical (Cerebrovascular events, Stroke) and economic (direct and indirect costs) data concerning patients who were managed in TIA clinic in Toulouse Hospital. The medical data will be compiled with available French and International literature. The economic data will be compiled with available data in PMSI and health insurance database. This study aims to prepare a multicenter cohort to compare the cost effectiveness ratio between ambulatory and conventional management.
Systemic sclerosis (SSc) is a rare autoimmune chronic disorder characterised by vascular hyper-reactivity and fibrosis of the skin as well as internal organs. Intimal hyperplasia, endothelial dysfunction and occlusive vasculopathy are the underlying basis of these chronic vascular damages. The expression of the vasculopathy especially includes Raynaud phenomenon (RP), digital ulcers (DUs), gastro-intestinal involvement and pulmonary arterial hypertension (PAH). Sicca syndrome is clinically characterised by dryness of the eyes (xerophthalmia) and mouth (xerostomia). The prevalence of sicca symptoms is up to 70% in prospective series of SSc patients. Sicca syndrome is supposed to be primarily related to glandular fibrosis. The prevalence of primary Sjögren Syndrome (pSS) among SSc patients, as defined by the American-European Consensus Group criteria is around 15%. Sicca syndrome is therefore a frequent feature in SSc and constitutes an important cause of quality of life's impairment in SSc If studies have already evaluated clinical and histological alterations of minor salivary glands secondary to sicca syndrome in SSc , only few studies used the recent ACR(American College of Rheumatology) 2013 classification criteria for SSc to select patients. SGUS(Salivary Gland UltraSonography) evaluation in SSc has never been assessed to date. Potential alterations of MSG (Major Salivary Gland) echostructure in SSc have never been described to date. The performances and reliability of SGUS to assessed MSG involvement in SSc are still to be determined. As fibrosis of salivary glands is supposed to be the main mechanism involved in SSc-associated sicca syndrome, measuring salivary-gland elasticity using ARFI-ultrasonography in SSc patients could also constitute a relevant method to assess the fibrosis of MSG in this disease. A cross-sectional pilot study is therefore needed to explore these relevant questions about sicca syndrome in SSc.
Each vial of Dantrium Intravenous should be reconstituted by adding 60 mL of sterile water for injection USP (without a bacteriostatic agent), and the vial shaken until the solution is clear. 5% Dextrose Injection USP, 0.9% Sodium Chloride Injection USP, and other acidic solutions are not compatible with Dantrium Intravenous and should not be used. The contents of the vial must be protected from direct light and used within 6 hours after reconstitution. Store reconstituted solutions between 15° to 30°C (59° to 86°F).

Reconstituted Dantrium Intravenous should not be transferred to large glass bottles for prophylactic infusion due to precipitate formation observed with the use of some glass bottles as reservoirs.

For prophylactic infusion, the required number of individual vials of Dantrium Intravenous should be reconstituted as outlined above. The contents of individual vials are then transferred to a larger volume sterile intravenous plastic bag. Stability data on file at Endo indicate commercially available sterile plastic bags are acceptable drug delivery devices. However, it is recommended that the prepared infusion be inspected carefully for cloudiness and/or precipitation prior to dispensing and administration. Such solutions should not be used. While stable for 6 hours, it is recommended that the infusion be prepared immediately prior to the anticipated dosage administration time.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
A controller assembly of a fluid delivery apparatus includes a body component and a plunger component slidably coupled to the body component. The plunger is positionable between a first position in which the plunger is nearest to the body component, and a second position in which the plunger component is furthest from the body component. A bias assembly positioned between the body component and the plunger component applies a two stage force profile to the plunger component. The bias assembly includes a first and a second biasing member. In the first position, the first and second biasing members apply first and second forces profiles, respectively, to the plunger component. In the second position, the first biasing member is prevented from applying the first force profile to the plunger component, and the second biasing member applies the second force profile to the plunger component.